Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene—a gene that can cause cancer—that may play an important role in colon cancer. Researchers also showed how this ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...
A research team led by Minyoung Lee and Sunggyu Park of The Korea Institute of Materials Science (KIMS) Bio & Health ...
The authors of the publication, from left to right: Maria Navarro, PhD, former member of the CGE, IGTP, currently working at Ability Pharmaceuticals, Nuria Mulet, MD PhD (ICO, B-ARGO), Cinta Hierro, ...
A new preclinical study led by researchers at The University of Texas MD Anderson Cancer Center and Weill Cornell Medicine has uncovered genetic and cell-state adaptive mechanisms that drive ...
ELI-002 2P vaccine targets KRAS mutation, showing reduced relapse risk and improved survival in pancreatic and colorectal cancer patients. Two-thirds of study participants exhibited a strong immune ...
July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results